Data / Drug companies / Scopolamine
Scopolamine: 12 companies and 16 products in the FDA NDC directory
Scopolamine is listed in the FDA National Drug Code Directory by 12 companies, with 16 products in commercial distribution. 15 of the products (93.8%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are patch, extended release; patch; system, and the newest product started marketing on June 11, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 12
- Products
- 16
- Generic (ANDA) products
- 15 (93.8%)
- Application numbers
- 7
- Routes
- Transdermal
- Brand names
- Transderm Scop
- openFDA record search
- api.fda.gov
Companies that list scopolamine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| A-S Medication Solutions | 3 | patch; system | Generic drugs (ANDA) | September 5, 2024 |
| Bryant Ranch Prepack | 3 | patch, extended release | Generic drugs (ANDA) | November 1, 2024 |
| Actavis Pharma, Inc. | 1 | system | Generic drugs (ANDA) | May 12, 2022 |
| Amneal Pharmaceuticals NY LLC | 1 | patch, extended release | Generic drugs (ANDA) | June 11, 2025 |
| Baxter Healthcare Company | 1 | patch, extended release | New drug applications (NDA) | December 1, 2016 |
| Bryant Ranch Prepack | 1 | patch, extended release | Generic drugs (ANDA) | November 1, 2024 |
| Ingenus Pharmaceuticals, LLC | 1 | patch, extended release | Generic drugs (ANDA) | November 24, 2020 |
| Mylan Pharmaceuticals Inc. | 1 | patch | Generic drugs (ANDA) | June 19, 2019 |
| NuCare Pharmaceuticals,Inc. | 1 | patch, extended release | Generic drugs (ANDA) | November 24, 2020 |
| Rhodes Pharmaceuticals LLC | 1 | patch, extended release | Generic drugs (ANDA) | November 1, 2024 |
| Zydus Lifesciences Limited | 1 | patch, extended release | Generic drugs (ANDA) | September 5, 2024 |
| Zydus Pharmaceuticals USA Inc. | 1 | patch, extended release | Generic drugs (ANDA) | September 5, 2024 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Patch, extended release | 12 | 75% |
| Patch | 2 | 12.5% |
| System | 2 | 12.5% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 15 | 93.8% |
| New drug applications (NDA) | 1 | 6.2% |
Pharmacologic classes
| Class | Products |
|---|---|
| Anticholinergic | 16 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.